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6Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, IranPomegranate (Punica granatum L.) juice (PJ) contains different types of antioxidants and bioactive polyphenols
and has been reported to promote cardiovascular health through several mechanisms. The present study aimed
to examine the effects of 2-week intake of fresh PJ on blood pressure, ﬂow-mediated dilatation (FMD), serum
lipid proﬁle and concentrations of inﬂammatory and endothelial function biomarkers. Twenty-one hypertensive
patients (aged 30–67 years) were recruited into the trial and assigned to receive either PJ (150ml/day in a single
occasion between lunch and dinner; n= 11) or the same amount of water (n= 10) for a period of 2weeks. Systolic
(SBP) and diastolic (DBP) pressures together with FMD and serum concentrations of lipid proﬁle parameters,
apolipoproteins A and B, intracellular adhesion molecule-1 (ICAM-1), vascular endothelial adhesion molecule
1 (VCAM-1), E-selectin, high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6) were measured
at baseline and at the end of trial. PJ consumption was associated with signiﬁcant reductions in SBP
(p= 0.002) and DBP (p= 0.038) but not FMD (p> 0.05). Serum levels of VCAM-1 (p= 0.008) were signiﬁcantly
reduced by PJ while those of E-selectin were elevated (p= 0.039). However, no signiﬁcant effect was observed
from PJ on serum levels of ICAM-1, hs-CRP, lipid proﬁle parameters, apolipoproteins and IL-6 in any of the
study groups (p> 0.05). Consumption of PJ for 2weeks has effective hypotensive effects, and may improve
endothelial function by decreasing serum concentrations of VCAM-1. These ﬁndings suggest PJ as a beneﬁcial
cardioprotective supplement for hypertensive subjects. Copyright © 2013 John Wiley & Sons, Ltd.
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Cardiovascular disease (CVD) encompasses a wide
range of abnormalities that initiate from atherosclerosis
and progresses over time into ischemic heart disease,
cardiomyopathy and acute coronary syndrome. CVD is
often accompanied by an increased production of free
radicals, most notably reactive oxygen species (ROS)
such as superoxide and hydroxyl radicals (Das and
Maulik, 1995). Increased generation of ROS in vascular
cells can interfere with normal anti-coagulation and anti-
inﬂammatory properties and induce several pathologic
abnormalities in the endothelium (Cai and Harrison,
2000). In light of the extensive research in the past two
decades, the classical view toward endothelium has been
changed drastically. Endothelium is no more considered
as a simple physical barrier between intravascular and
interstitial compartments, but a large and active organ
with endocrine functions as well as a pivotal role inondence to: Sedigheh Asgary, Isfahan Cardiovascular Research
rdiovascular Research Institute, Isfahan University of medical
sfahan, Iran.
gary@yahoo.com
© 2013 John Wiley & Sons, Ltd.maintaining vascular haemodynamics and homeostasis
(Marx and Grant, 2007).
Upon endothelium dysfunction, increased vascular
permeability allows plasma components including low-
density lipoprotein (LDL) to penetrate and deposit in
the subendothelial space. Thus, endothelial dysfunction
is considered to be the ﬁrst triggering step in the athero-
genesis process (Bonetti et al., 2003; Weissberg, 1999).
Impaired endothelial function is characterized by a
reduction in the bioavailability of nitric oxide (NO),
which is a potent vasodilator with anti-inﬂammatory
and anti-proliferative properties, and inhibitory activity
against platelet adhesion and aggregation (Deanﬁeld
et al., 2007; Furchgott and Zawadzki, 1980). Another
characteristic of endothelial dysfunction is overexpression
of cell adhesion molecules (CAMs), followed by their
release into the circulation. CAMs possess inﬂammatory
properties and mediate the marginalization, rolling and
tethering of leukocytes along the endothelium, thus
playing a pivotal role in the development and progression
of atherosclerosis (Ballantyne and Abe, 1997; Cybulsky
et al., 1999; Galkina and Ley, 2007). Endothelial function
is measured in vivo through measuring ﬂow-mediated
dilation (FMD) in the brachial artery. FMD has beenReceived 14 September 2012
Revised 20 February 2013
Accepted 23 February 2013
194 S. ASGARY ET AL.proven to be a strong predictor of cardiovascular events
(Gokce et al., 2002; Rossi et al., 2008; Widlansky et al.,
2003; Yeboah et al., 2007).
There is a strong pile of evidence indicating diverse
biological activities and health beneﬁts of plant phyto-
chemicals, in particular phenolics and ﬂavonoids
(Hodgson and Croft, 2010; Sahebkar, 2010a, b, Hu
et al., 2011; Xiao et al., 2011; Huang et al., 2012; Ikemura
et al., 2012; Mohammadi et al., 2012; Panahi et al., 2012a,
b; Sahebkar, 2012a, b; Shin et al., 2012). Large-scale
prospective cohorts have suggested an inverse associa-
tion between consumption of fruits and vegetables rich
in ﬂavonoids and CVD mortality (Liu et al., 2000; Mink
et al., 2007). Furthermore, an increasing number of epi-
demiological studies have consistently shown a protective
effect of foods rich in polyphenols (fruit, tea, wine, and
cocoa or chocolate and specially citrus fruit) against
several CVD risk factors such as LDL oxidation, hyper-
tension and endothelial dysfunction (Hamdy et al., 2003;
Keogh et al., 2005; Wu and Meininger, 2002).
Punica granatum L. (Punicaceae) fruit (Pomegranate)
is considered as a heart-healthy fruit juice (Basu and
Penugonda, 2009). Pomegranate is rich in polyphenolic
type antioxidants including tannins, anthocyanins
(de Nigris et al., 2007) and several other types of ﬂavo-
noids (Sudheesh et al., 1997). The soluble polyphenol
content in pomegranate juice (PJ) normally ranges
between 0.2 and 1.0%, depending on the variety, and
mainly comprises tannins, ellagic anthocyanins, cate-
chins, and gallic and ellagic acids (Ben Nasr et al., 1996).
In spite of the previously reported cardiovascular health
beneﬁts of pomegranate and its rich content of polyphe-
nols and ﬂavonoids (Anonymous, 2007; Basu and
Penugonda, 2009; Fuhrman and Aviram, 2007; Ross,
2009; Stowe, 2011), there have been very few studies on
the anti-hypertensive effects of PJ in clinical setting. In ad-
dition, the impact of PJ on endothelial function as well
as circulating levels of CAMs – as important mediators
in endothelial dysfunction and pathogenesis of athero-
sclerosis – has remained deeply unexplored, and its rich
content of polyphenols and ﬂavonoids led to the hypoth-
esis being tested in the present study, whether supplemen-
tation with PJ could ameliorate endothelial function and
lower blood pressure in hypertensive subjects.SUBJECTS AND METHODS
Subjects.Twenty-onehypertensivepatients aged 30–67years
were recruited for this trial. Patients were selected from
those referred to the Hypertension Clinic at the Isfahan
Cardiovascular Research Institute. The Ethics Commit-
tee at the Isfahan University of Medical Sciences
(Isfahan, Iran) approved the study protocol, and each
subject signed an informed consent form prior to the
study commencement. This study has been registered at
the Iranian Registry of Clinical Trials (www.IRCT.IR)
under registration number IRCT201206249662N4.
Study inclusion criteria were body mass index (BMI)
≤ 30, systolic blood pressure (SBP)> 140mmHg and/or
diastolic blood pressure (DBP)> 90mmHg. Exclusion
criteria were type 1 or 2 diabetes, chronic pancreatitis, liver
cirrhosis, kidney stones, renal failure, use of non-steroidal
anti-inﬂammatory drugs, use of antioxidant or vitamin
supplements, intense physical activity (> 5 h/week),Copyright © 2013 John Wiley & Sons, Ltd.smoking habit, being vegetarian or having any restric-
tive dietary requirements and pregnancy.
Study design. The present study was designed as a
single-blind clinical trial. Included subjects (n= 21) were
assigned to receive either natural PJ (Punica granatum
cv. ‘shirin’) (150ml/day) (n= 11) between lunch and
dinner or 150ml water (as placebo) at the same time
(n= 10). Patients were alternatively assigned to PJ or
control group. The treating physician and laboratory
staff remained blind as to the intervention type through-
out the study.
Test drinks and total anthocyanin determination. Pome-
granates were handpicked, washed and the entire fruit
then squeezed in a manual juicer. Determination of total
anthocyanins in PJ was performed using a pH differen-
tial method, as described previously (Lee et al., 2005).
The method is based on the structural transformations
and thereby change in the absorbance of anthocyanins
as a function of pH. At pH1, the colored oxonium form
is the predominant form of anthocyanins, while at pH
4.5, anthocyanins turn into colorless hemiketal form.
To assay anthocyanins, separate aliquots of PJ were
adjusted to pH1 and pH4.5 using potassium chloride
and sodium acetate buffers, respectively. Following
equilibrium, the absorbance of dilutions was read at 515
and 700nm. The difference in the absorbance of sample
is proportional to the anthocyanin content. The absor-
bance of diluted samples is calculated as follows:
A ¼ A 515 nmð ÞpH 1:0 A 700 nmð ÞpH 1:0
h i
 A 700 nmð ÞpH 4:5 A 700 nmð ÞpH 4:5
h i
Knowing the absorbance, the concentration of antho-
cyanins is calculated using the following equation:
Total anthocyanin content mg=100 mLð Þ
¼ AMW DFð Þ= e L Vð Þ
Where MW is the molecular weight (449.2 gmol1), e
is the molar extinction coefﬁcient (26.900 l cm1mol1),
DF is the dilution factor (2), l is the path length (1 cm) and
V is the initial sample volume (2ml). Total anthocyanin
content was expressed as mg of cyanidin-3-O-glucoside
per 100ml.
Anthropometric measurements. Height was measured
to the nearest 0.1 cm with a meter, with participants
being barefoot. Body weight was measured to the nearest
0.05kg using a calibrated digital scales (AMZ 14;
Mercury, Tokyo, Japan). The participants were wear-
ing light clothing and no footwear. BMI was calculated
as weight in kilograms divided by height in meters
squared (m2).
BP measurement. BP was measured at baseline and at
the end of trial according to a standard protocol. BP
recordings were performed after a rest, in the seated state
and using a stethoscope and a standard mercury sphyg-
momanometer. The SBP was deﬁned as the appearance
of the ﬁrst sound (Korotkoff phase 1) and the DBP was
deﬁned as the disappearance of the sound (Korotkoff
phase 5) during deﬂating of the cuff.Phytother. Res. 28: 193–199 (2014)
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the right brachial artery was measured at baseline as
well as at the end of trial under conditions described previ-
ously (Dickinson et al., 2009). FMD was measured follow-
ing a 5-min rest and by means of a GE vivid 3 Ultrasound
apparatus (AtCor Medical, Solingen, Germany). A BP
cuff was inﬂated around forearm to 200mmHg for 5min.
Images were recorded at baseline (before inﬂation), 30 s
before cuff release and then every 15 s after cuff release
for 3min. Arterial diameter was measured at the end of
end-diastolic phase, coinciding with R-wave on the
electrocardiogram. Brachial FMD was calculated as
the percentage of change from the baseline diameter.
In order to avoid any performance bias, the operator
who conducted FMD measurements was kept unaware
of the allocation type at the time of the test (Corretti
et al., 2002).
Venous blood collection. Overnight fasted blood sam-
ples (5ml) were collected from the left antecubital vein
between 8:00 and 9:30 am. Blood was taken into
vacutainer tubes without anti-coagulant, under quality
control and safety procedure. Serum was separated
from blood 2–3 h after sampling by centrifugation at
3500–4000 rpm for 10min. Collected sera were stored
at 80 C until analysis.
Biochemical analysis. Serum lipid proﬁle [comprising
total cholesterol, triglycerides, low- (LDL-C) and
high-density lipoprotein cholesterol (HDL-C)] along
with high-sensitivity C-reactive protein (hs-CRP) and
fasting blood sugar (FBS) were determined using an
automated enzymatic assay (Pars Azmoon, Tehran,
Iran) on a Hitachi 902 autoanalyzer. Serum concentra-
tion of adhesion molecules including intracellular
adhesion molecule-1 (ICAM-1), vascular endothelial
adhesion molecule 1 (VCAM-1) and E-selectin together
with interleukin-6 (IL-6) were measured by an enzyme-
linked immunosorbent assay method with commercial
kits (Boster Biological Technolog, Wuhun, China). Apo
B and Apo Awere quantiﬁed using a modiﬁed commer-
cially available immunoturbidimetric assay according to
the kit instructions (Pars Azmoon, Iran, Tehran).
Statistical analysis.All statistical analyses were performed
using SPSS software package for Windows. Data were
expressed as meansSD. Between-group comparisons
were made using independent samples t-test (for
normally distributed data) or Mann–Whitney U test (for
non-normally distributed data). Within-group compari-
sons were performed using paired t-test (for normally
distributed data) or Wilcoxon signed-ranks test (for
non-normally distributed data). Bivariate correlations
between changes in SBP, DBP and FMD, and anthropo-
metric and biochemical parameters were evaluated
using Pearson’s (in case of normally distributed data)
and Spearman’s (in case of non-normally distributed
data) correlation coefﬁcient. In addition, stepwise multi-
ple linear regression analysis was performed to identify
the parameters that could predict the changes in
SBP, DBP and FMD, as primary outcome measures
(dependent variables). Dependent variables that entered
into the model included changes in ICAM-1, VCAM-1,
E-selectin, hs-CRP, IL-6, total cholesterol, LDL-C, HDL-C,
triglycerides, apo A, apo B and FBS. A p-value of< 0.05
was considered as statistically signiﬁcant.Copyright © 2013 John Wiley & Sons, Ltd.RESULTS
Demographic ﬁndings
Baseline demographic biochemical parameters of PJ and
control groups are summarized in Table 1. The groups
were comparable regarding age, gender, weight, height,
waist circumference, BMI and FMD, as well as serum
concentrations of hs-CRP, IL-6, ICAM-1, VCAM-1, total
cholesterol, LDL-C, HDL-C and triglycerides (p> 0.05).
Likewise, no signiﬁcant difference was observed between
the study groups regarding their mean SBP and DBP
values at baseline (p> 0.05). However, serum E-selectin
(p< 0.001) and apo B (p=0.033) concentrations were
signiﬁcantly higher in the PJ compared to control group.Total anthocyanin content
Analysis of PJ indicated a total anthocyanin content of
5.8mg per 100ml of the administered juice.Effect of PJ on blood pressure and FMD
PJ consumption was found to be associated with signiﬁ-
cant reductions in mean systolic (p=0.002) and DBPs
(p=0.038) compared to the control group. However, no
signiﬁcant difference in the extent of FMD changes
was found between the groups (p> 0.05). Within- and
between-group changes in SBP, DBP and FMD during
the course of trial are summarized in Tables 2 and 3,
respectively.Effect of PJ on serum lipoprotein and
apolipoprotein concentrations
Magnitude of changes in serum lipid proﬁle parameters
(comprising total cholesterol, LDL-C, HDL-C and
triglycerides), apo A and apo B was comparable between
the PJ and control groups (p> 0.05) (Tables 2 and 3).Effect of PJ on endothelial function and
inﬂammatory biomarkers
Consumption of PJ was associated with a signiﬁcant
reduction in serum VCAM-1 concentrations (p=0.008).
In contrast, serum levels of E-selectin were elevated by
the end of trial in the PJ group (p=0.039). Differentials
for other parameters (ICAM-1, hs-CRP and IL-6) were
not found to be signiﬁcantly different between the study
groups (p> 0.05) (Tables 2 and 3).Correlation and regression analyses
In bivariate analyses, no signiﬁcant correlation was
found between changes in SBP and any of the assessed
parameters nor was any association for DBP and FMD
in the PJ group. In the control group, there was no
signiﬁcant change over the study period, neither in
SBP nor in DBP. However, signiﬁcant correlations were
found between changes in FMD and changes in thePhytother. Res. 28: 193–199 (2014)
Table 1. Baseline characteristics of the study groups
p-value Control group (n=10) Pomegranate juice group (n=11)
> 0.05 46.9012.36 58.915.06 Age (years)
> 0.05 70.0 72.7 Female (%)
> 0.05 73.505.98 68.0010.05 weight (kg)
> 0.05 161.709.46 159.186.03 Height (cm)
> 0.05 100.209.89 97.279.45 Waist circumference (cm)
> 0.05 27.954.14 26.79-3.47 BMI (kg/m2)
> 0.05 128.0013.17 130.9113.00 SBP (mmHg)
> 0.05 85.008.50 80.008.94 DBP (mmHg)
> 0.05 0.270.05 0.240.09 FMD (%)
> 0.05 0.960.54 1.821.58 Hs-CRP (ng/ml)
> 0.05 662.50175.59 577.36171.39 ICAM-1 (ng/ml)
> 0.05 517.60144.95 392.55164.46 VCAM-1 (ng/ml)
< 0.001 36.2737.61 122.6020.23 E-Selectin (ng/ml)
> 0.05 6.653.77 7.494.75 IL-6 (ng/ml)
> 0.05 118.1014.17 12.0514.75 Apo A (mg/dl)
0.033 73.9012.54 87.3914.15 Apo B (mg/dl)
> 0.05 187.4031.52 208.9138.21 TC (mg/dl)
> 0.05 39.706.55 48.737.51 HDL-C (mg/dl)
> 0.05 161.40125.60 149.0950.44 Triglycerides (mg/dl)
> 0.05 109.0026.80 125.0924.94 LDL-C (mg/dl)
> 0.05 87.8010.91 90.096.11 FBS (mg/dl)
Values are expressed as meanSD or %. BMI: body mass index; Hs-CRP: high-sensitivity C-reactive protein; ICAM-1: intracellular adhesion
molecule-1; VCAM-1: vascular cell adhesion molecule-1; IL-6: interleukin-6; apo A: apolipoprotein A; apo B: apolipoprotein B; TC: total
cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; FBS: fasting blood sugar.
Table 2. Pre- vs. post-trial values of the evaluated parameters in the study groups
Pomegranate juice group (n=11) Control group (n=10)
Baseline Post-trial p-value Baseline Post-trial p-value
FMD (%) 0.230.09 0.290.07 0.034 0.270.04 0.280.07 0.705
SBP (mmHg) 130.9113.00 124.5515.72 0.008 128.0013.17 128.0013.17 1.00
DBP (mmHg) 80.008.94 76.366.74 0.046 85.008.50 85.008.05 1.00
Hs-CRP (ng/ml) 1.811.57 1.492.28 0.050 91.008.75 91.008.75 0.269
ICAM-1 (ng/ml) 577.36171.39 524.36208.79 0.028 662.50177.58 654.20177.68 0.066
VCAM-1 (ng/ml) 392.55164.46 233.09107.87 0.008 517.60144.95 516.40148.76 0.635
E-Selectin (ng/ml) 122.5920.23 152.3333.69 0.050 36.2737.61 39.5445.70 0.109
IL-6 (ng/ml) 7.494.75 4.381.04 0.086 6.653.76 6.013.56 0.655
Apo A (mg/dl) 120.5014.74 122.6319.90 0.563 118.1014.16 118.70017.66 0.234
Apo B (mg/dl) 87.3914.15 93.1825.98 0.756 73.9012.53 72.3012.74 0.175
TC (mg/dl) 208.9138.20 218.7342.81 0.109 187.4031.51 187.0030.27 0.276
HDL-C (mg/dl) 48.737.51 49.278.06 0.507 39.706.55 40.406.91 0.276
Triglycerides (mg/dl) 149.0950.44 171.1878.92 0.401 161.40125.60 165.60124.32 0.141
LDL-C (mg/dl) 125.0924.94 127.2724.22 1.000 109.0026.80 109.4025.82 0.334
FBS (mg/dl) 90.096.10 90.647.004 0.528 87.8010.91 89.1011.34 0.240
Values are expressed as meanSD or %. BMI: body mass index; Hs-CRP: high-sensitivity C-reactive protein; ICAM-1: intracellular adhesion
molecule-1; VCAM-1: vascular cell adhesion molecule-1; IL-6: interleukin-6; apo A: apolipoprotein A; apo B: apolipoprotein B; TC: total
cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; FBS: fasting blood sugar.
196 S. ASGARY ET AL.following parameters: ICAM-1 (r=0.649; p= 0.042),
E-selectin (r= 0.702; p= 0.024), apo A (r=0.679;
p= 0.031), total cholesterol (r= 0.877; p= 0.001) and
IL-6 (r=0.784; p= 0.013). In stepwise linear regression
analysis, changes in SBP, DBP and FMD were sepa-
rately entered into the model as dependent variables.
Independent variables included changes in ICAM-1,
VCAM-1, E-selectin, hs-CRP, IL-6, total cholesterol,Copyright © 2013 John Wiley & Sons, Ltd.LDL-C, HDL-C, triglycerides, apo A, apo B and FBS.
Linear regression ﬁndings indicated that none of the
entered independent variables could predict changes in
SBP, DBP or FMD. However, in the control group,
changes in serum total cholesterol [OR: 0.719; 95% CI:
0.023–0.061); p= 0.001] and apo A [OR: 0.384; 95%
CI: 0.012–0.001); p= 0.026] were found as signiﬁcant
confounders of FMD changes during the course of trial.Phytother. Res. 28: 193–199 (2014)
Table 3. Comparison of the magnitude of changes in the evaluated parameters between the study groups
Groups PJ group 95% CI Control group 95% CI p-value
FMD (%) 0.050.07 0.008 – 0.10 0.010.09 0.05 – 0.07 0.208
SBP (mmHg) 6.365.05 9.75 – 2.97 0.000.00 - 0.002
DBP (mmHg) 3.645.05 7.03 – 0.25 0.000.00 - 0.038
Hs-CRP (ng/ml) 0.330.89 0.93 – 0.27 0.170.42 0.13 – 0.47 0.124
ICAM-1 (ng/ml) 53.0079.72 106.56 – 0.56 8.3015.00 19.03 – 2.43 0.096
VCAM-1 (ng/ml) 159.40158.86 266.18 – 52.73 1.207.73 6.73 – 4.33 0.008
E-Selectin (ng/ml) 29.7436.53 5.20 – 54.28 3.278.36 0.039
IL-6 (ng/ml) 3.114.82 6.35 – 0.13 0.632.36 2.32 – 1.06 0.387
Apo A (mg/dl) 2.1418.65 10.39 – 14.66 0.604.97 2.96 – 4.16 0.797
APO B (mg/dl) 5.8024.70 10.80 – 22.38 1.603.57 4.15 – 0.95 0.349
TC (mg/dl) 9.8232.82 12.23 – 31.87 0.401.51 1.48 – 0.68 0.327
HDL-C (mg/dl) 0.552.58 1.19 – 2.28 0.701.77 0.56 – 1.96 0.863
TG (mg/dl) 22.0958.13 16.96 – 61.14 4.2010.60 3.38 – 11.78 0.338
LDL-C (mg/dl) 2.1823.36 13.51 – 17.88 0.401.78 0.87 – 1.67 0.806
FBS mg/dl 0.553.30 1.67 – 2.76 1.301.34 0.34 – 2.26 0.509
Values are expressed asmeanSDplus 95%confidence interval or%. BMI: bodymass index; Hs-CRP: high-sensitivity C-reactive protein; ICAM-1:
intracellular adhesionmolecule-1; VCAM-1: vascular cell adhesionmolecule-1; IL-6: interleukin-6; apo A: apolipoprotein A; apo B: apolipoprotein
B; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; FBS: fasting blood sugar.
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The results of this study demonstrated that consumption
of PJ is associated with signiﬁcant hypotensive effects.
In addition, interesting reduction of serum VCAM-1
was observed, suggesting potential efﬁcacy of PJ against
endothelial dysfunction and vascular inﬂammation.
Nonetheless, FMD was not signiﬁcantly altered by PJ
despite promising within-group improvement. A previous
trial among hypertensive adults documented a dose–
response relationship between increased fruit and vegeta-
ble consumption and improved FMD (Castilla et al.,
2008). Recent studies have investigated the beneﬁcial
effects of anthocyanin-rich fruit juices such as cranberry
and blood orange juice in subjects with coronary artery
disease. Although such products could reduce carotid
femoral pulse wave velocity andmitigate arterial stiffness,
they had no effect on brachial artery FMD (Dohadwala
et al., 2011; George et al., 2009; Morand et al., 2011). Since
a marked reduction of FMD was observed in the PJ but
not control group, PJ appears to be more efﬁcacious in
the improvement of endothelial function compared with
the above mentioned beverages. PJ has a high content
of anthocyanins, vitamin C and carotenoids, which are
all micronutrients known to exert cardioprotective and
endothelial ameliorating effects (George et al., 2009).
Serum elevation of E-selectin by PJ was a somewhat
contradictory ﬁnding as there was a decreasing trend for
other evaluated CAMs following PJ supplementation.
This ﬁnding could be partially attributed to the higher
baseline concentrations of E-selectin in the PJ compared
to control group, resulting in a greater effect size and
increased likelihood of detecting a signiﬁcant difference
in the PJ group.
The principal ﬁnding of the present study is that
2-weeks consumption of PJ signiﬁcantly decreases DBP
and SBP in hypertensive patients. This is consistent with
the ﬁndings of a previous study in daily consumption of
50ml of PJ for two weeks was reported to cause a 5%
decline in SBP (Aviram and Dornfeld, 2001). In this
latter study, a marked reduction in serum angiotensin-Copyright © 2013 John Wiley & Sons, Ltd.converting enzyme activity (36%) was also observed
which justiﬁes the observed hypotensive effects. In
another trial by Aviram et al. (2004), consumption of PJ
for one year was found to be associated with about 21%
reduction in SBP and signiﬁcant decreases in carotid
intima-media thickness, LDL-oxidation, anti-oxidized
LDL antibody titers. Furthermore, serum paraoxonase-
1 activity, along with total antioxidant status, was
augmented by PJ consumption. Similar to the present
results, no effect on lipid proﬁle parameters as well as
apo A and apo B levels was observed. In addition, DBP
values remained unaltered by the end of trial. This dis-
crepancy in DBP changes could be attributed to the
basic difference in the study populations as participants
of the Aviram et al. (2004) study were patients with
severe carotid artery stenosis whereas the present study
recruited hypertensive patients. Further to the BP lower-
ing activity, PJ has been shown to possess considerable
anti-atherosclerotic antioxidant and anti-inﬂammatory
effects in both human subjects and mouse models
(Stowe, 2011).
Hs-CRP is a sensitive marker of vascular inﬂammation
and an emerging risk factor for CVD (Libby, 2006).
Although between-group comparisons implied a decreas-
ing trend in serum hs-CRP following PJ consumption, no
signiﬁcant effect was observed in the between-group
analysis. The most plausible explanation for not detecting
any signiﬁcant difference between the study groups in
terms of hs-CRP and FMD is the limited number of
subjects which makes the study underpowered for these
parameters. As another ﬁnding, PJ exerted favorable
effects on the circulating levels of endothelial adhesion
molecules. This is an interesting ﬁnding as upregulation
of endothelial adhesion molecules, including E-selectin,
ICAM-1 and VCAM-1, play a crucial role in the earliest
phases of atherosclerosis (Blankenberg et al., 2003;
Gonzalez and Selwyn, 2003).
Unlike the aforementioned parameters, no signiﬁcant
alteration was found in the serum levels of IL-6, apo A,
apo B and lipid proﬁle parameters. While the possibility
of a lack of effectiveness on these indices is not
excluded, a deﬁnitive judgment requires studies withPhytother. Res. 28: 193–199 (2014)
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PJ. Heretofore, a number of bioactive molecules with
anti-inﬂammatory effects have been identiﬁed in
pomegranate. These phytochemicals, e.g. punicalagin,
punicalin, strictinin A and granatin B, have been shown
to reduce the generation of nitric oxide and PGE2 by
inhibiting the expression of pro-inﬂammatory proteins
(Lee et al., 2008; Romier et al., 2008). Overall, the most
frequent and bioactive class of compounds in PJ appear
are polyphenols. PJ contains higher levels of polyphe-
nolic compounds than other fruit juices, such as
grapefruit, orange, apple and cranberry juice (Basu and
Penugonda, 2009). The major polyphenols in the PJ
include ellagitannins and anthocyanins, which are
believed to contribute to cardiovascular health via a wide
range of activities, e.g. antioxidant, anti-inﬂammatory and
immunomodulatory actions (Gil et al., 2000; Lansky and
Newman, 2007).Limitations
The present study was limited in a number of ways:
First, the patients were not blinded with respect to the
intervention. This is in part due to the distinct taste
and appearance of PJ which makes the preparation of
a matched placebo treatment a very hard task. Second,
the alternative assignment of participants to PJ and
control groups hindered concealment of allocations
from the administering physician. Third, no food fre-
quency questionnaire was used nor daily intake of fruits
and vegetables was monitored in the present trial.
Hence, it remains unclear that group differences in the
intake of micro- and macronutrients had any signiﬁcant
effect on the alterations observed in the evaluated param-
eters. Fourth, PJ in the present trial was characterized as
to a single class of phytochemicals namely anthocyanins.
It is suggested that future studies provide a more compre-
hensive phytochemical analysis, characterize PJ with
respect to other phytochemical subsets (e.g. total pheno-
lics, ﬂavonoids, tannins, carotenoids, n-3 polyunsaturated
fatty acids etc) and standardize the administered dosage
based on the total antioxidant intake. Finally, the study
population size was relatively few due to the pilot design,
and this might have negatively inﬂuenced the power toCopyright © 2013 John Wiley & Sons, Ltd.detect signiﬁcant differences in a number of parameters.
Therefore, future randomized double-blind trials are
warranted to conﬁrm the preliminary ﬁndings found in
this pilot trial in larger populations and over a longer
period of time. The impact of PJ consumption on FMD
– as the main outcome measure for the assessment of
endothelial function – is of particular interest as there
was trend toward improvement of FMD in the present
study but this did not reach statistical signiﬁcance,
probably due to the study being underpowered for this
outcome. Testing the effect of consuming different PJ
volumes is also greatly recommended to determine if
larger volumes of intake are associated with enhanced
hypotensive and anti-inﬂammatory effects.CONCLUSION
In summary, ﬁndings from the present pilot trial pro-
vided evidence for the beneﬁcial impact of PJ consump-
tion on both systolic and DBPs in hypertensive
individuals. Besides, consumption of PJ was found to
be associated with signiﬁcant reductions in serum
VCAM-1 which is a biomarker of endothelial function
and vascular inﬂammation. In light of these promising
ﬁndings, PJ may be considered as an effective adjunct
to the anti-hypertensive medications and also as a con-
stituent of daily regimen for patients who are high risk
for hypertension and CVD. However, any deﬁnitive
judgment on the efﬁcacy of PJ remains to be made in
light of the ﬁndings of future larger scale and double-
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